cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.11435112
title: Extracellular vesicles and their role in glioblastoma

description: Research on the role of extracellular vesicles (EVs) in disease pathogenesis has been rapidly growing over the last two decades. As EVs can mediate intercellular communication, they can ultimately facilitate both normal and pathological processes through the delivery of their bioactive cargo, which may include nucleic acids, proteins and lipids. EVs have emerged as important regulators of brain tumors, capable of transferring oncogenic proteins, receptors, and small RNAs that may support brain tumor progression, including in the most common type of brain cancer, glioma. Investigating the role of EVs in glioma is crucial, as the most malignant glioma, glioblastoma (GBM), is incurable with a dismal median survival of 12–15 months. EV research in GBM has primarily focused on circulating brain tumor-derived vesicles in biofluids, such as blood and cerebrospinal fluid (CSF), investigating their potential as diagnostic and prognostic biomarkers. Gaining a greater understanding of the role of EVs and their cargo in brain tumor progression may contribute to the discovery of novel diagnostics and therapeutics. In this review, we summarize the known and emerging functions of EVs in glioma biology and pathogenesis, as well as their emerging biomarker potential.
DOI: 10.6084/m9.figshare.11435112.v1
title: Extracellular vesicles and their role in glioblastoma

description: Research on the role of extracellular vesicles (EVs) in disease pathogenesis has been rapidly growing over the last two decades. As EVs can mediate intercellular communication, they can ultimately facilitate both normal and pathological processes through the delivery of their bioactive cargo, which may include nucleic acids, proteins and lipids. EVs have emerged as important regulators of brain tumors, capable of transferring oncogenic proteins, receptors, and small RNAs that may support brain tumor progression, including in the most common type of brain cancer, glioma. Investigating the role of EVs in glioma is crucial, as the most malignant glioma, glioblastoma (GBM), is incurable with a dismal median survival of 12–15 months. EV research in GBM has primarily focused on circulating brain tumor-derived vesicles in biofluids, such as blood and cerebrospinal fluid (CSF), investigating their potential as diagnostic and prognostic biomarkers. Gaining a greater understanding of the role of EVs and their cargo in brain tumor progression may contribute to the discovery of novel diagnostics and therapeutics. In this review, we summarize the known and emerging functions of EVs in glioma biology and pathogenesis, as well as their emerging biomarker potential.
DOI: 10.6084/m9.figshare.11434965
title: Double-balloon enteroscopy for retrieving retained small-bowel video capsule endoscopes: a systematic review

description: <b>Background and aim:</b> Capsule retention is the most common adverse event associated with video capsule endoscopy. The use of double-balloon enteroscopy-assisted capsule endoscope retrieval has been increasingly reported in recent years. However, evidence is limited regarding its success rate, associated factors, and subsequent clinical outcomes. <b>Methods:</b> A systematic review of relevant studies published before January 2019 was performed. Successful retrieval rate and associated factors, rate of endoscopic balloon dilation, and outcomes after double-balloon enteroscopy were summarized and pooled. <b>Results:</b> Within 154 associated original articles, 12 including 150 cases of capsule retrieval by double-balloon enteroscopy were included. The estimated pooled successful retrieval rate was 86.5% (95% confidence interval, 75.6–95.1%). Anterograde approach and capsules retained in the jejunum or trapped by malignant strictures were associated with a higher successful retrieval rate than the retrograde approach (62/83 [74.7%] vs. 10/38 [26.3%], <i>p</i> p p = .043). Endoscopic balloon dilation was performed in 38.8% (95% confidence interval, 22.3–56.3%) of patients with benign strictures. Two perforations (1.3%) were reported as severe adverse events after double-balloon enteroscopy. A significantly lower surgery rate was found among cases with successful video capsule removal compared with unsuccessful cases (7.2% vs. 38.5%, <i>p</i> = .002). <b>Conclusions:</b> Double-balloon enteroscopy is feasible and safe for removing retained video capsule endoscopes, and its use could decrease the need for surgery in patients with benign strictures and facilitate subsequent surgery in patients with malignant strictures.
DOI: 10.6084/m9.figshare.11432943
title: HNP3 DataForRepos 191211.xlsx

description: This excelfile contains the data used in a manuscript, as of 2019-10-28 called ‘Gait asymmetries of horses walking and trotting on treadmill with and without rider’. Responsible for the data is Agneta Egenvall:
DOI: 10.6084/m9.figshare.11432127
title: Nord & Cooper Ibis 2019_Eastern Bluebird data.xlsx

description: Data from Nord, A & Cooper, C.B. Night conditions affect morning incubation behaviour differently across a latitudinal gradient. Ibis. https://doi.org/10.1111/ibi.12804
DOI: 10.6084/m9.figshare.11432127.v1
title: Nord & Cooper Ibis 2019_Eastern Bluebird data.xlsx

description: Data from Nord, A & Cooper, C.B. Night conditions affect morning incubation behaviour differently across a latitudinal gradient. Ibis. https://doi.org/10.1111/ibi.12804
DOI: 10.6084/m9.figshare.11432943.v1
title: HNP3 DataForRepos 191211.xlsx

description: This excelfile contains the data used in a manuscript, as of 2019-10-28 called ‘Gait asymmetries of horses walking and trotting on treadmill with and without rider’. Responsible for the data is Agneta Egenvall:
DOI: 10.6084/m9.figshare.11432100
title: Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs

description: <b>Introduction</b>: Obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile including significant weight reduction with these agents compared to placebo. <b>Areas covered</b>: We systematically searched the database of PubMed, Embase, The Cochrane Library and The ClinicalTrials.gov up to 30 September 2019 and retrieved all the randomized controlled trials (RCTs) that were conducted with these five drugs for ≥1 year and explicitly reported their efficacy versus placebo. Subsequently, we have conducted the meta-analysis to primarily study the effect of these anti-obesity drugs on weight reduction. We additionally reviewed the effect of these drugs on other cardio-metabolic parameters including key adverse events. <b>Expert opinion</b>: This meta-analysis finds a significant reduction in body weight with orlistat (N = 10,435; ∆ −3.07 Kg, 95% CI, −3.76 to −2.37), phentermine plus topiramate (N = 2985; ∆ −9.77 Kg; 95% CI, −11.73 to −7.81), lorcaserin (N = 16,856; ∆ −3.08 Kg; 95% CI, –3.49 to –2.66), naltrexone plus bupropion (N = 3239; ∆ −4.39 Kg; 95% CI, −5.05 to −3.72) and liraglutide (N = 4978; ∆ −5.25 Kg; 95% CI, −6.17 to −4.32), compared to placebo (all p &lt; 0.00001).
DOI: 10.6084/m9.figshare.11432100.v1
title: Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs

description: <b>Introduction</b>: Obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile including significant weight reduction with these agents compared to placebo. <b>Areas covered</b>: We systematically searched the database of PubMed, Embase, The Cochrane Library and The ClinicalTrials.gov up to 30 September 2019 and retrieved all the randomized controlled trials (RCTs) that were conducted with these five drugs for ≥1 year and explicitly reported their efficacy versus placebo. Subsequently, we have conducted the meta-analysis to primarily study the effect of these anti-obesity drugs on weight reduction. We additionally reviewed the effect of these drugs on other cardio-metabolic parameters including key adverse events. <b>Expert opinion</b>: This meta-analysis finds a significant reduction in body weight with orlistat (N = 10,435; ∆ −3.07 Kg, 95% CI, −3.76 to −2.37), phentermine plus topiramate (N = 2985; ∆ −9.77 Kg; 95% CI, −11.73 to −7.81), lorcaserin (N = 16,856; ∆ −3.08 Kg; 95% CI, –3.49 to –2.66), naltrexone plus bupropion (N = 3239; ∆ −4.39 Kg; 95% CI, −5.05 to −3.72) and liraglutide (N = 4978; ∆ −5.25 Kg; 95% CI, −6.17 to −4.32), compared to placebo (all p &lt; 0.00001).
DOI: 10.6084/m9.figshare.11430576
title: MOESM1 of Inventory and new records of benthic amphipods from macrophytes and fine sand communities of the Bizerte lagoon (Tunisia, SW Mediterranean Sea)

description: Additional file 1. Description of the sampling stations in the Bizerte lagoon (depths, coordinates, habitats) and sampling methods used in the present study.
DOI: 10.6084/m9.figshare.11430576.v1
title: MOESM1 of Inventory and new records of benthic amphipods from macrophytes and fine sand communities of the Bizerte lagoon (Tunisia, SW Mediterranean Sea)

description: Additional file 1. Description of the sampling stations in the Bizerte lagoon (depths, coordinates, habitats) and sampling methods used in the present study.
DOI: 10.6084/m9.figshare.11430522
title: MOESM4 of Bayesian smoothed small-areas analysis of urban inequalities in fertility across 1999–2013

description: Additional file 4. Supplementary results
DOI: 10.6084/m9.figshare.11430522.v1
title: MOESM4 of Bayesian smoothed small-areas analysis of urban inequalities in fertility across 1999–2013

description: Additional file 4. Supplementary results
DOI: 10.6084/m9.figshare.11430501
title: MOESM2 of Comparison of methylation patterns generated from genomic and cell-line derived DNA using the Illumina Infinium MethylationEPIC BeadChip array

description: Additional file 2: Table S1. Illumina Bead Array Controls Reporter for the gDNA and clDNA samples. Table S2. Top-ranked differentially methylated CpG sites for gDNA vs. clDNA (group 1). Table S3. Top-ranked differentially methylated CpG sites for gDNA vs. clDNA (group 2). Table S4. Top-ranked CpG sites which differed between groups 1 and 2 (gDNA vs. clDNA - ST2 and ST3). Table S5. Top-ranked CpG sites which were common between groups 1 and 2 (gDNA vs. clDNA - ST2 and ST3). Table S6. GO enrichment analysis for genes where top-ranked CpG sites are located. Table S7. Enriched pathways (KEGG) for genes where top-ranked CpG sites are located.
DOI: 10.6084/m9.figshare.11430501.v1
title: MOESM2 of Comparison of methylation patterns generated from genomic and cell-line derived DNA using the Illumina Infinium MethylationEPIC BeadChip array

description: Additional file 2: Table S1. Illumina Bead Array Controls Reporter for the gDNA and clDNA samples. Table S2. Top-ranked differentially methylated CpG sites for gDNA vs. clDNA (group 1). Table S3. Top-ranked differentially methylated CpG sites for gDNA vs. clDNA (group 2). Table S4. Top-ranked CpG sites which differed between groups 1 and 2 (gDNA vs. clDNA - ST2 and ST3). Table S5. Top-ranked CpG sites which were common between groups 1 and 2 (gDNA vs. clDNA - ST2 and ST3). Table S6. GO enrichment analysis for genes where top-ranked CpG sites are located. Table S7. Enriched pathways (KEGG) for genes where top-ranked CpG sites are located.
DOI: 10.6084/m9.figshare.11430414
title: MOESM1 of Men’s knowledge and involvement on obstetric danger signs, birth preparedness and complication readiness in Burayu town, Oromia region, Ethiopia

description: Additional file 1: Questionnaire for Men’s Knowledge on Obstetric Danger Signs, Birth Preparedness and Complication Readiness.
DOI: 10.6084/m9.figshare.11430414.v1
title: MOESM1 of Men’s knowledge and involvement on obstetric danger signs, birth preparedness and complication readiness in Burayu town, Oromia region, Ethiopia

description: Additional file 1: Questionnaire for Men’s Knowledge on Obstetric Danger Signs, Birth Preparedness and Complication Readiness.
DOI: 10.6084/m9.figshare.11430402
title: MOESM9 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 9. Genes upregulated by digitoxin treatment and gene therapy against IB3-1 controls annotated to epithelial differentiation ontologies, and compared in parallel to effects of VX-661, VX-770 and VX-809.
DOI: 10.6084/m9.figshare.11430402.v1
title: MOESM9 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 9. Genes upregulated by digitoxin treatment and gene therapy against IB3-1 controls annotated to epithelial differentiation ontologies, and compared in parallel to effects of VX-661, VX-770 and VX-809.
DOI: 10.6084/m9.figshare.11430396
title: MOESM8 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 8. Genes down-regulated by both digitoxin treatment and gene therapy.
DOI: 10.6084/m9.figshare.11430396.v1
title: MOESM8 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 8. Genes down-regulated by both digitoxin treatment and gene therapy.
DOI: 10.6084/m9.figshare.11430390
title: MOESM7 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 7. Genes up-regulated by both digitoxin treatment and gene therapy.
DOI: 10.6084/m9.figshare.11430390.v1
title: MOESM7 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 7. Genes up-regulated by both digitoxin treatment and gene therapy.
DOI: 10.6084/m9.figshare.11430384
title: MOESM6 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 6. Functional Gene Ontology themes for [wildtype]CFTR Gene Therapy, and Drug-specific changes in CF lung Epithelial cells.
DOI: 10.6084/m9.figshare.11430384.v1
title: MOESM6 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 6. Functional Gene Ontology themes for [wildtype]CFTR Gene Therapy, and Drug-specific changes in CF lung Epithelial cells.
DOI: 10.6084/m9.figshare.11430375
title: MOESM5 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 5. Influence of digitoxin and VX-770 on chlorideÂ transport by FRT cells with the [G551D]CFTR mutation.
DOI: 10.6084/m9.figshare.11430375.v1
title: MOESM5 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 5. Influence of digitoxin and VX-770 on chlorideÂ transport by FRT cells with the [G551D]CFTR mutation.
DOI: 10.6084/m9.figshare.11430372
title: MOESM4 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 4. Influence of digitoxin and multiple VX drugs on cytokine and chemokine secretion from CF IB3â€“1 cells.
DOI: 10.6084/m9.figshare.11430372.v1
title: MOESM4 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 4. Influence of digitoxin and multiple VX drugs on cytokine and chemokine secretion from CF IB3â€“1 cells.
DOI: 10.6084/m9.figshare.11430366
title: MOESM3 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 3. Influence of digitoxin and individual VX drugs on cytokine and chemokine secretion from CF IB3â€“1 cells.
DOI: 10.6084/m9.figshare.11430366.v1
title: MOESM3 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 3. Influence of digitoxin and individual VX drugs on cytokine and chemokine secretion from CF IB3â€“1 cells.
DOI: 10.6084/m9.figshare.11430357
title: MOESM2 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 2. Abbreviations.
DOI: 10.6084/m9.figshare.11430357.v1
title: MOESM2 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 2. Abbreviations.
DOI: 10.6084/m9.figshare.11430354
title: MOESM1 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 1. Materials and Methods.
DOI: 10.6084/m9.figshare.11430354.v1
title: MOESM1 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 1. Materials and Methods.
DOI: 10.6084/m9.figshare.11430345
title: MOESM2 of Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer

description: Additional file 2. Microarray data and statistical analyses
DOI: 10.6084/m9.figshare.11430348
title: MOESM18 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 18. Comparison of genes up-regulated by digitoxin treatment and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to epithelial differentiation processes versus Affymetrix log2 expression fold-changes from CF patients treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post-treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430342
title: MOESM17 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 17. Comparison of genes down-regulated by digitoxin and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to fibrotic processes versus Affymetrix log2 expression fold-changes from CF patients treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430345.v1
title: MOESM2 of Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer

description: Additional file 2. Microarray data and statistical analyses
DOI: 10.6084/m9.figshare.11430348.v1
title: MOESM18 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 18. Comparison of genes up-regulated by digitoxin treatment and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to epithelial differentiation processes versus Affymetrix log2 expression fold-changes from CF patients treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post-treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430339
title: MOESM1 of Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer

description: Additional file 1. miRNA screening data and statistical analyses
DOI: 10.6084/m9.figshare.11430342.v1
title: MOESM17 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 17. Comparison of genes down-regulated by digitoxin and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to fibrotic processes versus Affymetrix log2 expression fold-changes from CF patients treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430339.v1
title: MOESM1 of Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer

description: Additional file 1. miRNA screening data and statistical analyses
DOI: 10.6084/m9.figshare.11430333
title: MOESM15 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 15. Effects of digitoxin on licensed VX-drug and drug combinations on increased expression of genes common to digitoxin and AAV-[wildtype]CFTR for the functional theme of epithelial differentiation.
DOI: 10.6084/m9.figshare.11430336
title: MOESM16 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 16. Comparison of genes down-regulated by digitoxin treatment and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to inflammatory processes versus Affymetrix log2 expression fold-changes from CF patoents treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post-treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430333.v1
title: MOESM15 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 15. Effects of digitoxin on licensed VX-drug and drug combinations on increased expression of genes common to digitoxin and AAV-[wildtype]CFTR for the functional theme of epithelial differentiation.
DOI: 10.6084/m9.figshare.11430336.v1
title: MOESM16 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 16. Comparison of genes down-regulated by digitoxin treatment and gene therapy in IB3-1 cells compared to controls by RNA-seq and annotated to inflammatory processes versus Affymetrix log2 expression fold-changes from CF patoents treated with 0.1 mg daily digitoxin for 28 days (pre-treatment vs post-treatment, Zeitlin et al, 2017).
DOI: 10.6084/m9.figshare.11430327
title: MOESM9 of Comparison of the transcriptomes of two tardigrades with different hatching coordination

description: Additional file 9: Table S1. Summary of RNA-Seq data.
DOI: 10.6084/m9.figshare.11430330
title: MOESM14 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 14. Effects of digitoxin on licensed VX-drug and drug combinations on reduced expression of mRNAs common to digitoxin and AAV-[wildtype]CFTR for the functional GO theme of cell-cell interactions/fibrosis.
DOI: 10.6084/m9.figshare.11430327.v1
title: MOESM9 of Comparison of the transcriptomes of two tardigrades with different hatching coordination

description: Additional file 9: Table S1. Summary of RNA-Seq data.
DOI: 10.6084/m9.figshare.11430330.v1
title: MOESM14 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 14. Effects of digitoxin on licensed VX-drug and drug combinations on reduced expression of mRNAs common to digitoxin and AAV-[wildtype]CFTR for the functional GO theme of cell-cell interactions/fibrosis.
DOI: 10.6084/m9.figshare.11430324
title: MOESM13 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 13. Effects of digitoxin on licensed VX-drug and drug combinations on reduced expression of mRNAs common to digitoxin and AAV-[wildtype]CFTR for the functional GO theme of inflammation.
DOI: 10.6084/m9.figshare.11430324.v1
title: MOESM13 of Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

description: Additional file 13. Effects of digitoxin on licensed VX-drug and drug combinations on reduced expression of mRNAs common to digitoxin and AAV-[wildtype]CFTR for the functional GO theme of inflammation.